

WOMEN AND HEART DISEASE

PATIENT GUIDE

Your symptoms may indicate a blockage in your heart—or they may not.

Now, a simple blood test can help your doctor know.

CORUS[®] CAD



Symptoms may include:
CHEST DISCOMFORT, SHORTNESS OF BREATH, HEARTBURN, OR BACK PAIN

Corus[®] CAD is a blood test that helps your doctor assess the likelihood that you have a blockage in your heart, also known as obstructive CAD*.

Women can exhibit different symptoms than men, such as chest discomfort, shortness of breath, heartburn, or back pain. These symptoms suggestive of obstructive coronary artery disease (CAD) are more varied and less obvious than the symptoms men often exhibit, which makes diagnosing their root cause more difficult. Traditional cardiac stress tests, such as an EKG treadmill test, myocardial perfusion imaging (MPI), and stress echocardiography, don't account for the cardiovascular differences between men and women, which is one of the reasons your doctor may want to use a test that does.^{†,1-4}

Now, a simple blood test can help provide the answer.

Corus CAD is the *only* sex-specific test designed to help your doctor assess the likelihood that you have a blocked artery in your heart. The test is simple, accurate[‡] and is the only test that takes into consideration key cardiovascular differences between men and women.

**PLEASE TALK TO YOUR DOCTOR
TO FIND OUT IF THE CORUS CAD
TEST IS RIGHT FOR YOU.**



Avoid invasive and time-consuming procedures.

With Corus CAD and other clinical information about you, your doctor may be able to safely and conveniently rule out the need for further evaluation for obstructive CAD as the cause of your symptoms. Not only does this help you achieve peace of mind sooner, but it can also help you minimize potentially unnecessary cardiac testing and procedures and exposure to harmful radiation.

How it works and how it's performed.

Corus CAD measures the activity, or gene expression, of genes, which is combined with age and sex to generate a score. The score indicates the likelihood that you have a significant narrowing or blockage in your heart arteries. The effectiveness of the test has been validated in two U.S. clinical studies called PREDICT and COMPASS.^{5,6}

The Corus CAD test is intended for patients who have symptoms that may be signs of blocked arteries in the heart, such as:

- Chest discomfort, pain, or tightness
- Shortness of breath
- Heartburn
- Back pain

The Corus CAD test is NOT intended for patients who have been previously diagnosed with a heart attack, had a previous invasive (surgical) procedure to open a blocked or narrowed artery, are diabetic, or are currently taking steroids, immunosuppressive agents, or chemotherapeutic agents.



If you have questions regarding insurance coverage or financial assistance for the Corus[®] CAD test, call our Customer Service team at 1.866.941.4996 or e-mail service@cardiodx.com.

To learn more, visit www.cardiodx.com or call us at 1.866.941.4996.



CARDIODX[®]

CardioDx
600 Saginaw Drive
Redwood City, CA 94063
P 866.941.4996
www.cardiodx.com

Customer Service
service@cardiodx.com
P 866.941.4996

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies.

*Obstructive CAD is defined as at least one atherosclerotic plaque causing $\geq 50\%$ luminal diameter stenosis in a major coronary artery ($\geq 1.5\text{mm}$ lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or core-lab computed tomography angiography (CTA) ($\geq 2.0\text{mm}$).

†Sensitivity of MPI in women demonstrated to be 78% vs. 85% in men. Sensitivity of EKG in women demonstrated to be 61% vs. 68% in men.

‡The COMPASS study found that the Corus CAD algorithm has an NPV of 96% at the pre-specified threshold of 15 in the overall population of men and women referred to MPI.

REFERENCES:

1. Kwok Y, Kim C, Grady D, et al. Meta-Analysis of Exercise Testing to Detect Coronary Artery Disease in Women. *Am J Cardiol*. 1999;83(5):660-665. 2. Burrell S, MacDonald A. Artifacts and Pitfalls in Myocardial Perfusion Imaging. *J Nucl Med Technol*. 2006;34(4):193-211. 3. Mora S, Redberg RF, Cui Y, et al. Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women: A 20-Year Follow-up of the Lipid Research Clinics Prevalence Study. *JAMA*. 2003;290(12):1600-1607. 4. Dolor RJ, Patel MR, Melloni C, et al. Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women. *Comparative Effectiveness Review No. 58*. AHRQ Publication No. 12-EHC034-EF. June 2012. 5. Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. *Ann Intern Med*. 2010;153:425-434. 6. Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. *Circ Cardiovasc Genet*. 2013;6(2):154-162.